Loading clinical trials...
Loading clinical trials...
Robotic Retroperitoneal Lymph Node Dissection (R-RPLND) as First-line Treatment for Clinical Stage IIA/B Testicular Seminoma
Conditions
Interventions
Robotic Retroperitoneal Lymph Node Dissection (RPLND)
Locations
1
Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Start Date
February 23, 2022
Primary Completion Date
November 1, 2030
Completion Date
November 1, 2030
Last Updated
December 19, 2025
Lead Sponsor
University Health Network, Toronto
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions